CompletedPhase 1NCT01284582

Safety, Immunogenicity and Dose Response of ATH03, a New Vaccine Against the Cholesterol Ester Transfer Protein (CETP)

Studying Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Affiris AG
Principal Investigator
Achim Schneeberger, MD
Affiris AG
Intervention
ATH03(biological)
Enrollment
36 enrolled
Eligibility
18-65 years · MALE
Timeline
20112012

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01284582 on ClinicalTrials.gov

Other trials for Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

Additional recruiting or active studies for the same condition.

See all trials for Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia

← Back to all trials